Dr. Brett A. English Joins Apex as VP of Scientific Affairs

Dr. Brett A. English Joins Apex as VP of Scientific Affairs

Apex Innovative Sciences Appoints Brett A. English, Pharm.D., Ph.D., as Vice President of Scientific Affairs

MARLTON, N.J. and GARDEN GROVE, Calif., April 8, 2021 — Apex Innovative Sciences (“Apex”), an industry-leading independent provider of clinical drug development and trial site services, today announced the appointment of Brett A. English, Pharm.D., Ph.D., as Vice President of Scientific Affairs.

“Brett’s background as a clinical researcher and scientist, combined with his experience planning and leading drug development programs for pharmaceutical companies, will enable us to build on Apex’s strong foundation and expand our consultative development work with sponsors,” said Howard Hassman, D.O., AOBFP, Chief Executive Officer of Apex.

Dr. English will provide scientific oversight, guidance, and training to Apex’s sites, Hassman Research Institute in New Jersey and CNS Research in California. He will also provide consultation and support services, including protocol development and program planning, to pharmaceutical companies of all sizes.

“There is increasing demand for creative de-risking solutions in drug development. Sponsors are looking to Apex to partner in program development and to incorporate novel biomarker strategies into their protocols,” commented Larry Ereshefsky, Pharm.D., BCPP, Apex’s Chief Scientific Officer. “Brett’s expertise in program planning and electrophysiology, imaging, and pharmacodynamic biomarker applications will be invaluable to our clients. Having worked in tandem with Brett for several years earlier in our careers, I know he will make an immense contribution to Apex.”

Dr. English brings to Apex over 15 years of experience as a clinical scientist and Principal Investigator on Phase I-III trials in central nervous system disorders. Prior to joining Apex, he spent three years at Arena Pharmaceuticals, serving as the Senior Director, Clinical Development and Global Clinical Development Lead for a novel cannabinoid 2 receptor agonist, Olorinab (APD371), for the treatment of visceral pain in patients with IBS. From 2016 to 2018, he was Associate Director, Clinical Development/Department Head, Early Phase Clinical Development at Dart NeuroScience where he was responsible for several early phase compounds and translational medicine programs. From 2011 to 2016, he was Senior Director, Scientific Affairs (Translational Neuroscience) at Parexel International where he was instrumental to the growth and expansion of Parexel’s early phase services. Dr. English has extensive experience within the Department of Veterans Affairs and Department of Defense medical programs and conducted trials evaluating PK/PD and pharmacogenetics of psychotropic drugs in the VA Research and Development system for several years. In addition to his professional medical and scientific experience, he also serves as a Commander (O-5) Medical Service Corps Officer in the United States Navy Reserve. For more about Dr. English, download his bio.

“I am excited to be joining the Apex team to lead activities to enhance study capabilities and to assist pharma sponsors in de-risking drug development,” said Dr. English. “I look forward to utilizing my experience in diverse settings to develop and support successful strategies requiring specialized technologies and scientific and regulatory guidance.”

About Apex Innovative Sciences
A global provider of clinical development and site services, Apex represents the consolidation of core businesses including CNS Research and Hassman Research Institute, industry-leading sites providing high quality study conduct for a wide range of Phase I-IV trials in healthy subjects, patient populations, and special populations. Apex prides itself on delivering scientific, technological, and clinical excellence at the speed needed to provide optimal value to clients. Apex’s expertise in program planning and protocol development helps sponsors reduce development costs and supports faster and more confident go/no-go decisions. For more information, please visit: www.apexsci.com

Bobbie Theodore, M.S.
VP, Sponsor Relations/BD